Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Validation of a prediction model for long-term outcome of aphasia after stroke.

Nouwens F, Visch-Brink EG, El Hachioui H, Lingsma HF, van de Sandt-Koenderman MWME, Dippel DWJ, Koudstaal PJ, de Lau LML.

BMC Neurol. 2018 Oct 15;18(1):170. doi: 10.1186/s12883-018-1174-5.

2.

Efficacy of early cognitive-linguistic treatment for aphasia due to stroke: A randomised controlled trial (Rotterdam Aphasia Therapy Study-3).

Nouwens F, de Lau LM, Visch-Brink EG, van de Sandt-Koenderman WM, Lingsma HF, Goosen S, Blom DM, Koudstaal PJ, Dippel DW.

Eur Stroke J. 2017 Jun;2(2):126-136. doi: 10.1177/2396987317698327. Epub 2017 Mar 10.

3.

Screening tests for aphasia in patients with stroke: a systematic review.

El Hachioui H, Visch-Brink EG, de Lau LM, van de Sandt-Koenderman MW, Nouwens F, Koudstaal PJ, Dippel DW.

J Neurol. 2017 Feb;264(2):211-220. doi: 10.1007/s00415-016-8170-8. Epub 2016 Jun 3. Review.

4.

Early effect of intra-arterial treatment in ischemic stroke on aphasia recovery in MR CLEAN.

Crijnen YS, Nouwens F, de Lau LM, Visch-Brink EG, van de Sandt-Koenderman MW, Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Roos YB, van der Lugt A, van Oostenbrugge RJ, van Zwam WH, Majoie CB, Dippel DW; MR CLEAN investigators.

Neurology. 2016 May 31;86(22):2049-55. doi: 10.1212/WNL.0000000000002724. Epub 2016 May 11.

PMID:
27170565
5.

Short Door-to-Needle Times in Acute Ischemic Stroke and Prospective Identification of Its Delaying Factors.

Van Schaik SM, Scott S, de Lau LM, Van den Berg-Vos RM, Kruyt ND.

Cerebrovasc Dis Extra. 2015 Jun 12;5(2):75-83. doi: 10.1159/000432405. eCollection 2015 May-Aug.

6.

Optimal timing of speech and language therapy for aphasia after stroke: more evidence needed.

Nouwens F, Visch-Brink EG, Van de Sandt-Koenderman MM, Dippel DW, Koudstaal PJ, de Lau LM.

Expert Rev Neurother. 2015;15(8):885-93. doi: 10.1586/14737175.2015.1058161. Epub 2015 Jun 18. Review.

PMID:
26088694
7.

[Chronic insomnia: not always psychophysiological].

Neerings-Verberkmoes NE, Vlak MH, de Lau LM, Hamburger HL.

Ned Tijdschr Geneeskd. 2014;158:A6791. Dutch.

PMID:
24988149
8.

Survival in Parkinson's disease. Relation with motor and non-motor features.

de Lau LM, Verbaan D, Marinus J, van Hilten JJ.

Parkinsonism Relat Disord. 2014 Jun;20(6):613-6. doi: 10.1016/j.parkreldis.2014.02.030. Epub 2014 Mar 12.

PMID:
24679900
9.

Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients.

Sonneveld MA, van Dijk AC, van den Herik EG, van Loon JE, de Lau LM, van der Lugt A, Koudstaal PJ, de Maat MP, Leebeek FW.

Atherosclerosis. 2013 Oct;230(2):210-5. doi: 10.1016/j.atherosclerosis.2013.07.046. Epub 2013 Aug 2.

10.

Relation of clinical subtypes in Parkinson's disease with survival.

de Lau LM, Verbaan D, van Rooden SM, Marinus J, van Hilten JJ.

Mov Disord. 2014 Jan;29(1):150-1. doi: 10.1002/mds.25652. Epub 2013 Sep 3. No abstract available.

PMID:
24038593
11.

Rotterdam Aphasia Therapy Study (RATS)-3: "The efficacy of intensive cognitive-linguistic therapy in the acute stage of aphasia"; design of a randomised controlled trial.

Nouwens F, Dippel DW, de Jong-Hagelstein M, Visch-Brink EG, Koudstaal PJ, de Lau LM; RATS-3 investigators.

Trials. 2013 Jan 23;14:24. doi: 10.1186/1745-6215-14-24.

12.

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.

de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ.

Mov Disord. 2012 Jan;27(1):132-5. doi: 10.1002/mds.23805. Epub 2011 Nov 14.

PMID:
22083803
13.

Association of two single nucleotide polymorphisms from genomewide association studies with clinical phenotypes of cerebral ischemia.

van den Herik EG, de Lau LM, Mohamad A, Ikram MA, Koudstaal PJ.

Int J Stroke. 2012 Apr;7(3):219-23. doi: 10.1111/j.1747-4949.2011.00658.x. Epub 2011 Oct 20.

PMID:
22011019
14.

Fibrinogen γ' levels in patients with intracerebral hemorrhage.

van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, Koudstaal PJ, de Maat MP.

Thromb Res. 2012 Jun;129(6):807-9. doi: 10.1016/j.thromres.2011.08.017. Epub 2011 Sep 13.

15.

γ'/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke.

van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, Koudstaal PJ, de Maat MP.

Thromb Haemost. 2011 Mar;105(3):430-4. doi: 10.1160/TH10-09-0569. Epub 2010 Dec 6.

PMID:
21136017
16.

A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke.

de Lau LM, Leebeek FW, de Maat MP, Koudstaal PJ, Dippel DW.

Int J Stroke. 2010 Oct;5(5):385-94. doi: 10.1111/j.1747-4949.2010.00468.x. Review.

PMID:
20854623
17.

Screening for coagulation disorders in patients with ischemic stroke.

de Lau LM, Leebeek FW, de Maat MP, Koudstaal PJ, Dippel DW.

Expert Rev Neurother. 2010 Aug;10(8):1321-9. doi: 10.1586/ern.10.104. Review.

PMID:
20662756
18.

Acute disseminating encephalomyelitis following legionnaires disease.

de Lau LM, Siepman DA, Remmers MJ, Terwindt GM, Hintzen RQ.

Arch Neurol. 2010 May;67(5):623-6. doi: 10.1001/archneurol.2010.75.

PMID:
20457963
19.

Predicting and preventing stroke after transient ischemic attack.

de Lau LM, den Hertog HM, van den Herik EG, Koudstaal PJ.

Expert Rev Neurother. 2009 Aug;9(8):1159-70. doi: 10.1586/ern.09.71. Review.

PMID:
19673605
20.

Genomewide association studies of stroke.

Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, Folsom AR, van den Herik EG, Bos MJ, Beiser A, Cushman M, Launer LJ, Shahar E, Struchalin M, Du Y, Glazer NL, Rosamond WD, Rivadeneira F, Kelly-Hayes M, Lopez OL, Coresh J, Hofman A, DeCarli C, Heckbert SR, Koudstaal PJ, Yang Q, Smith NL, Kase CS, Rice K, Haritunians T, Roks G, de Kort PL, Taylor KD, de Lau LM, Oostra BA, Uitterlinden AG, Rotter JI, Boerwinkle E, Psaty BM, Mosley TH, van Duijn CM, Breteler MM, Longstreth WT Jr, Wolf PA.

N Engl J Med. 2009 Apr 23;360(17):1718-28. doi: 10.1056/NEJMoa0900094. Epub 2009 Apr 15.

21.

[Parkinson disease is more prevalent than people think. Research results].

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM.

Ned Tijdschr Geneeskd. 2009 Jan 17;153(3):63-8. Dutch. No abstract available.

PMID:
19235340
22.

Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke.

de Lau LM, Cheung EY, Kluft C, Leebeek FW, Meijer P, Laterveer R, Dippel DW, de Maat MP.

Br J Haematol. 2008 Dec;143(5):734-7. doi: 10.1111/j.1365-2141.2008.07395.x.

PMID:
19036017
23.

Acute CNS white matter lesions in patients with inflammatory bowel disease.

de Lau LM, de Vries JM, van der Woude CJ, Kuipers EJ, Siepman DA, Sillevis Smitt PA, Hintzen RQ.

Inflamm Bowel Dis. 2009 Apr;15(4):576-80. doi: 10.1002/ibd.20792.

PMID:
19023898
24.

Genetic variation in homocysteine metabolism, cognition, and white matter lesions.

de Lau LM, van Meurs JB, Uitterlinden AG, Smith AD, Refsum H, Johnston C, Breteler MM.

Neurobiol Aging. 2010 Nov;31(11):2020-2. doi: 10.1016/j.neurobiolaging.2008.10.004. Epub 2008 Nov 18.

PMID:
19019492
25.

Plasma vitamin B12 status and cerebral white-matter lesions.

de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM.

J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):149-57. doi: 10.1136/jnnp.2008.149286. Epub 2008 Oct 31.

PMID:
18977824
26.

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM.

Neuroepidemiology. 2007;28(4):193-6. Epub 2007 Sep 11.

PMID:
17851257
27.

Plasma folate concentration and cognitive performance: Rotterdam Scan Study.

de Lau LM, Refsum H, Smith AD, Johnston C, Breteler MM.

Am J Clin Nutr. 2007 Sep;86(3):728-34.

PMID:
17823439
28.

Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease.

de Lau LM, Stricker BH, Breteler MM.

Mov Disord. 2007 Oct 15;22(13):1985. No abstract available.

PMID:
17557354
29.

Number of children and risk of Parkinson's disease.

Frigerio R, Breteler MM, de Lau LM, Sanft KR, Bower JH, Ahlskog JE, Grossardt BR; Mariza de Andrade, Maraganore DM, Rocca WA.

Mov Disord. 2007 Apr 15;22(5):632-9.

PMID:
17265462
30.

Serum cholesterol levels and the risk of Parkinson's disease.

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM.

Am J Epidemiol. 2006 Nov 15;164(10):998-1002. Epub 2006 Aug 11.

PMID:
16905642
31.

Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease.

de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM.

Neurology. 2006 Jul 25;67(2):315-8.

PMID:
16864826
32.

Epidemiology of Parkinson's disease.

de Lau LM, Breteler MM.

Lancet Neurol. 2006 Jun;5(6):525-35. Review.

PMID:
16713924
33.

Subjective complaints precede Parkinson disease: the rotterdam study.

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM.

Arch Neurol. 2006 Mar;63(3):362-5. Epub 2006 Jan 9.

PMID:
16401729
34.

Serum uric acid levels and the risk of Parkinson disease.

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM.

Ann Neurol. 2005 Nov;58(5):797-800.

PMID:
16240356
35.

Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study.

de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM.

Arch Neurol. 2005 Aug;62(8):1265-9.

PMID:
16087767
36.

Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study.

de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM.

Neurology. 2005 Jun 28;64(12):2040-5.

PMID:
15985568
37.

Methylenetetrahydrofolate reductase C677T genotype and PD.

de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM.

Ann Neurol. 2005 Jun;57(6):927-30.

PMID:
15929053
38.

Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.

de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM.

Neurology. 2004 Oct 12;63(7):1240-4.

PMID:
15477545

Supplemental Content

Loading ...
Support Center